Ameritas Investment Partners Inc. Sells 550 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Ameritas Investment Partners Inc. decreased its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX) by 33.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,106 shares of the company’s stock after selling 550 shares during the period. Ameritas Investment Partners Inc.’s holdings in Nkarta were worth $35,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Citigroup Inc. raised its position in Nkarta by 1,682.8% during the first quarter. Citigroup Inc. now owns 76,198 shares of the company’s stock valued at $2,507,000 after purchasing an additional 71,924 shares in the last quarter. Millennium Management LLC raised its position in Nkarta by 1,796.2% during the first quarter. Millennium Management LLC now owns 241,231 shares of the company’s stock valued at $7,936,000 after purchasing an additional 228,509 shares in the last quarter. Rhumbline Advisers raised its position in Nkarta by 12.2% during the first quarter. Rhumbline Advisers now owns 20,870 shares of the company’s stock valued at $687,000 after purchasing an additional 2,273 shares in the last quarter. Northern Trust Corp raised its position in Nkarta by 4.5% during the first quarter. Northern Trust Corp now owns 221,640 shares of the company’s stock valued at $7,292,000 after purchasing an additional 9,461 shares in the last quarter. Finally, Sectoral Asset Management Inc purchased a new stake in Nkarta during the first quarter valued at about $5,562,000. 73.30% of the stock is owned by institutional investors.

NKTX opened at $31.29 on Friday. The company has a market cap of $1.03 billion, a P/E ratio of -13.97 and a beta of 1.03. The business’s 50-day moving average price is $32.35 and its 200-day moving average price is $32.07. Nkarta, Inc. has a 12 month low of $23.02 and a 12 month high of $79.16.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings data on Thursday, August 12th. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.06). Analysts expect that Nkarta, Inc. will post -2.69 earnings per share for the current year.

NKTX has been the topic of a number of research reports. Oppenheimer initiated coverage on Nkarta in a research report on Thursday, July 15th. They set an “outperform” rating and a $75.00 price target on the stock. Mizuho restated a “buy” rating and set a $81.00 price target on shares of Nkarta in a research report on Wednesday, June 16th. Cantor Fitzgerald lifted their price objective on Nkarta from $71.00 to $78.00 and gave the stock an “overweight” rating in a report on Tuesday, June 29th. Finally, Zacks Investment Research upgraded Nkarta from a “sell” rating to a “hold” rating in a report on Thursday, August 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $76.00.

In related news, insider Ralph Brandenberger sold 4,140 shares of the firm’s stock in a transaction dated Wednesday, September 1st. The stock was sold at an average price of $32.08, for a total value of $132,811.20. Following the sale, the insider now directly owns 340 shares of the company’s stock, valued at $10,907.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kanya Rajangam sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 5th. The stock was sold at an average price of $37.28, for a total value of $372,800.00. The disclosure for this sale can be found here. Insiders sold 29,140 shares of company stock worth $937,911 over the last three months. 12.60% of the stock is owned by insiders.

Nkarta Profile

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Recommended Story: Treasury Bonds

Want to see what other hedge funds are holding NKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nkarta, Inc. (NASDAQ:NKTX).

Institutional Ownership by Quarter for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.